Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations
12-week certificate course commences on March 10th 2022
This has further strengthened its manufacturing presence in the United States of America
110 BDS graduates admitted in week one of the launch
Vonjo is the first approved therapy to specifically address the needs of adult cytopenic myelofibrosis patients
Clinical trial supply company strengthens its presence in the European Union
The method shows the removal of seven types of PFAS – even when all of them are found in the same unit of fluid – at a level of efficiency that approaches 90%, and it does so within a few minutes
These results are being presented at the 2022 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
Allogeneic discogenic cell therapy was well tolerated and produced clinically meaningful, statistically significant improvements in low back pain, function, and quality of life by 12 weeks following intradiscal injection
The joint initiative is called J-ARC Healthcare Solutions
Subscribe To Our Newsletter & Stay Updated
